Cardiac Amyloid Biorepository

study id #: NCT05521503

condition: Cardiac Amyloidosis

status: Recruiting

Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by cardiac amyloidosis and therapeutic interventions.

results: https://clinicaltrials.gov/ct2/show/results/NCT05521503

last updated: February 22, 2024

start date: December 21, 2021

estimated completion: December 2027

last updated: August 22, 2023

size / enrollment: 400

study description: This is a prospective study enrolling patients referred for or undergoing cardiac amyloidosis or cardiovascular treatment at the University of Kentucky. The study aims to facilitate the discovery of novel diagnostic biomarkers and therapeutic targets and improve the pathophysiological understanding of cardiac amyloidosis.

primary outcomes:

• Discover and quantify the concentration of novel diagnostic and prognostic biomarkers
  Use biospecimens procured from patients with cardiac amyloidosis to identify diagnostic surrogate biomarkers using discovery proteomics. The serum levels will be compared between confirmed ATTR and non-ATTR heart failure patients and a diagnostic threshold will be established.
• 12/21/2021-12/31/2027
  

inclusion criteria:

exclusion criteria: Criteria:

Patients without a cardiovascular or amyloidosis diagnosis, under 18 years of age.

sponsor: Andrew Kolodziej

contacts: Andrew R Kolodziej, MD, (859) 562-0902, [email protected]

investigators: Andrew R Kolodziej, MD,University Of Kentucky

trial center locations: United States

• United States, Kentucky
  University of Kentucky
  Andrew Kolodziej, MD, 859-562-0902, [email protected]